Erkelenz

Researchers are evaluating asthma control, health-related quality of life (HRQL), lung function, and asthma medication use in patients with severe eosinophilic asthma treated with benralizumab in a real-life clinical setting in Germany. This prospective, non-interventional, single-arm, multicenter study aims to observe these outcomes over a 52-week period to better understand benralizumab's impact outside of randomized clinical trials. Patients prescribed benralizumab according to label and local reimbursement criteria will be followed for up to 52 weeks. The study will monitor asthma control using the Asthma Control Test (ACT) and the Asthma Impairment and Risk Questionnaire (AIRQ®) at various timepoints. Health-related quality of life will be assessed with the mini Asthma Quality of Life Questionnaire (miniAQLQ) at baseline and routine follow-up visits. Patients will also track and report their weekly asthma medication intake using either paper-based or electronic diaries throughout the study. Participants will complete questionnaires every 4 weeks and record medication intake weekly. Researchers will measure changes in ACT scores, proportions of responders, and reductions in inhaled corticosteroid doses from baseline to weeks 12, 24, and 52. Safety and health outcomes will be observed under routine clinical care. This study includes adults aged 18 to 120 years with severe eosinophilic asthma who can understand study instructions and provide informed consent.

Researchers are evaluating the long-term effects of Dupilumab treatment on patients with Chronic Obstructive Pulmonary Disease (COPD) in a real-world setting over 24 months. The study focuses on changes in health-related quality of life, patient characteristics, effectiveness, and safety of Dupilumab for those whose COPD remains uncontrolled despite standard therapies and who have elevated blood eosinophils. This is a non-interventional study where patients receive Dupilumab as prescribed by their doctors according to approved guidelines, without any treatment administered by the study itself. Dupilumab treatment initiation happens independently from study recruitment, and patient data is collected during routine clinical care. Participants will be involved for up to 12 months with assessments including monitoring changes in the COPD Assessment Test (CAT) score from baseline. Data is gathered through clinical evaluations and patient-reported outcomes. Safety and effectiveness are observed through regular documentation of clinical health and patient experiences during their ongoing treatment.